Specialty Overview

Best Hospitals for Pancreatic Cancer Treatment in Chennai, India

8 surgical oncology hospitals in our India network are listed in Chennai, accredited by JCI, NABH, NABL, with 4,035 beds combined.

8
Hospitals Listed
1
City
4.5
Avg. Rating
3
Accreditation Types
The Short Answer

This page lists the surgical oncology hospitals in our directory offering Pancreatic Cancer Treatment in Chennai, India, including Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital and others. Each listing links through to the hospital's full profile page.

Ask us about pancreatic cancer treatment in Chennai, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 8 accredited hospitals for Surgical Oncology in Chennai, India

🇮🇳 Apollo Hospitals, Greams Road

Chennai, India 4.7 (125 reviews) 560 beds
Why consider this hospital?
4.7/5 rating from 125 reviewsAccredited by JCI, NABH560 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH
4.7/5
Rating
1983
Established
560
Beds
Chennai, India
Location
Gleneagles Global Hospital

🇮🇳 Gleneagles Global Hospital

Chennai, India 4.7 (112 reviews) 1,000 beds
Why consider this hospital?
4.7/5 rating from 112 reviewsAccredited by NABH, JCI1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by NABH, JCI
4.7/5
Rating
1999
Established
1,000
Beds
Chennai, India
Location
Dr. Rela Institute and Medical Centre

🇮🇳 Dr. Rela Institute and Medical Centre

Chennai, India 4.7 (108 reviews) 450 beds
Why consider this hospital?
4.7/5 rating from 108 reviewsAccredited by NABH, NABL450 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by NABH, NABL
4.7/5
Rating
2018
Established
450
Beds
Chennai, India
Location
SIMS Hospital

🇮🇳 SIMS Hospital

Chennai, India 4.6 (20 reviews) 345 beds
Why consider this hospital?
4.6/5 rating from 20 reviewsAccredited by NABH, JCI345 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantOrthopedicsGastroenterology
Accredited by NABH, JCI
4.6/5
Rating
1970
Established
345
Beds
Chennai, India
Location
Sankara Nethralaya

🇮🇳 Sankara Nethralaya

Nungambakkam, Chennai, India 4.4 (220 reviews) 200 beds
Why consider this hospital?
4.4/5 rating from 220 reviewsAccredited by NABH, NABL200 beds
Specialties & Accreditation
OphthalmologyRetina SurgeryCornea TransplantGlaucomaPediatric Ophthalmology
Accredited by NABH, NABL
4.4/5
Rating
1978
Established
200
Beds
Nungambakkam, Chennai, India
Location
Apollo First Med Hospitals, Kilpauk

🇮🇳 Apollo First Med Hospitals, Kilpauk

Kilpauk, Chennai, India 4.4 (76 reviews) 80 beds
Why consider this hospital?
4.4/5 rating from 76 reviewsAccredited by NABH, JCI80 beds
Specialties & Accreditation
Cardiac SciencesOrthopedicsNeurologyOncologyGastroenterology
Accredited by NABH, JCI
4.4/5
Rating
2002
Established
80
Beds
Kilpauk, Chennai, India
Location
MIOT International

🇮🇳 MIOT International

Manapakkam, Chennai, India 4.4 (200 reviews) 1,000 beds
Why consider this hospital?
4.4/5 rating from 200 reviewsAccredited by NABH, NABL, JCI1,000 beds
Specialties & Accreditation
OrthopedicsCardiac SurgeryNeurosciencesTransplantOncology
Accredited by NABH, NABL, JCI
4.4/5
Rating
1999
Established
1,000
Beds
Manapakkam, Chennai, India
Location
MGM Healthcare

🇮🇳 MGM Healthcare

Chennai, India 3.7 (34 reviews) 400 beds
Why consider this hospital?
3.7/5 rating from 34 reviewsAccredited by NABH, JCI400 beds
Specialties & Accreditation
Cardiac SurgeryNeurosciencesTransplantCancer CareOrthopedics
Accredited by NABH, JCI
3.7/5
Rating
1970
Established
400
Beds
Chennai, India
Location
Our Methodology

How we selected these hospitals

A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Pancreatic Cancer Treatment in Chennai, India?

Choosing the right hospital for pancreatic cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include surgical oncology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Pancreatic Cancer Treatment

Pancreatic cancer treatment encompasses a spectrum of interventions — from curative-intent Whipple procedures and distal pancreatectomies to advanced systemic therapies including FOLFIRINOX, gemcitabine-nab-paclitaxel combinations, and precision-targeted PARP inhibitors for BRCA-mutated tumors. Resection in high-volume centers achieves 5-year survival rates of 20–25% for Stage I–II disease, while multimodal protocols for locally advanced cases continue to improve median overall survival. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed cancer hospitals in Dubai and Abu Dhabi, offering world-class surgical and oncologic expertise at a fraction of Western costs, with full end-to-end logistical support.

7–21 days (varies by treatment modality: 7–10 days for Whipple/pancreatectomy; shorter for chemotherapy initiation cycles)
Hospital Stay
4–8 weeks post-surgery for major resection; 2–3 weeks after chemotherapy cycle initiation, subject to oncologist clearance
Total Stay in Country (Fit-to-Fly)
20–25% 5-year survival for resectable (Stage I–II) disease; median overall survival of 12–18 months for locally advanced disease with multimodal therapy
Success Rate

Clinical Overview

Pancreatic cancer — most commonly pancreatic ductal adenocarcinoma (PDAC) — arises from the exocrine cells lining the pancreatic ducts and accounts for approximately 90% of all pancreatic malignancies. Because the pancreas is a deeply retroperitoneal organ with rich lymphovascular proximity to the superior mesenteric artery (SMA), portal vein, and celiac axis, early-stage disease is largely asymptomatic, resulting in over 80% of cases being diagnosed at locally advanced (Stage III) or metastatic (Stage IV) stages. Physiologically, tumor involvement disrupts both exocrine function — leading to malabsorption, steatorrhea, and significant weight loss — and endocrine function, frequently inducing new-onset diabetes mellitus. Obstructive jaundice due to common bile duct compression is a hallmark presentation in pancreatic head tumors and is managed with endoscopic retrograde cholangiopancreatography (ERCP) stenting prior to definitive surgery.

Full details →

Who is a Candidate?

  • ELIGIBLE FOR SURGICAL RESECTION (Whipple / Distal Pancreatectomy / Total Pancreatectomy):

- Pathologically or radiologically confirmed pancreatic ductal adenocarcinoma, acinar cell carcinoma, or pancreatic neuroendocrine tumor (pNET)

- Radiologically resectable disease: no arterial abutment of SMA, celiac axis, or hepatic artery; no venous occlusion of SMV/portal vein beyond reconstructable limits

Full details →

Treatment Options & Approaches

Surgical APPROACHES:

1. Pancreaticoduodenectomy (Whipple Procedure) — Standard & Pylorus-Preserving (PPPD):

The gold-standard curative resection for pancreatic head and uncinate process tumors. En bloc removal of the pancreatic head, duodenum, proximal jejunum, gallbladder, and common bile duct, with reconstruction via pancreaticojejunostomy, hepaticojejunostomy, and gastro/duodenojejunostomy. The pylorus-preserving modification (PPPD) maintains the stomach and pylorus, reducing post-gastrectomy complications while maintaining oncologic equivalence. Vascular resection and reconstruction of the SMV/portal vein axis (segmental resection with primary anastomosis or interposition graft) is performed in borderline resectable cases at high-volume centers.

2. Distal Pancreatectomy with Splenectomy (DP-CAM for left-sided tumors):

Full details →

Recovery

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2):

  • Patient submits medical records (pathology report, imaging DICOM files, prior treatment summaries) to GAF Healthcare's medical team
  • GAF Healthcare oncology coordinators arrange a virtual multidisciplinary tumor board (MDT) review with the treating surgeon, medical oncologist, and interventional radiologist at the selected partner hospital
  • Treatment plan confirmed: surgery vs. neoadjuvant chemotherapy first vs. systemic therapy
  • GAF Healthcare initiates e-Medical Visa application (India) or UAE entry visa facilitation
  • Pre-travel fitness assessment: cardiology clearance, nutritional optimization, glycemic control for diabetic patients
  • Arrangements: airport transfer, hospital-adjacent accommodation for 1–2 attendants

PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in-country):

Full details →

Risks to be aware of

Pancreatic cancer treatment carries a meaningful spectrum of procedural and oncologic risks that patients must understand transparently. For the Whipple procedure (pancreaticoduodenectomy), the most clinically significant complication is Post-Operative Pancreatic Fistula (POPF), occurring in 10–25% of cases and classified Grade A (biochemical leak), B (requiring intervention), or C (life-threatening) per ISGPS criteria; Grade B/C fistulas may require percutaneous drain insertion, radiologic intervention, or re-operation. Delayed Gastric Emptying (DGE) affects 20–30% of patients, prolonging hospital stay by 5–10 days on average and requiring nutritional support via nasojejunal feeding. Post-pancreatectomy haemorrhage (PPH) is rare (<5%) but potentially life-threatening, with sentinel bleed from the gastroduodenal artery stump being a recognized early warning. Bile leak occurs in approximately 5–10% of cases and is managed with ERCP stenting or percutaneous drainage in most instances. Total pancreatectomy mandates lifelong insulin-dependent diabetes management and carries risks of severe brittle hypoglycemia, necessitating experienced endocrinology support. General surgical risks include wound infection (10–15%), pulmonary complications including pneumonia and atelectasis (10%), deep vein thrombosis and pulmonary embolism (3–5% despite prophylaxis), and anastomotic stricture requiring late endoscopic intervention. For systemic chemotherapy, FOLFIRINOX carries significant cumulative neurotoxicity (peripheral neuropathy in >50% of patients), myelosuppression with febrile neutropenia risk (5–10%), and severe diarrhea and fatigue; dose modifications are routine. Gemcitabine-nab-paclitaxel carries risks of peripheral neuropathy, myelosuppression, and alopecia. PARP inhibitors (olaparib) are associated with anemia, nausea, and rare pneumonitis. Oncologically, even after R0 resection, the 5-year overall survival remains 20–25% for Stage I–II disease, and patients must be counseled about the high recurrence risk (70–80% within 2 years), most commonly to the liver and peritoneum. At GAF Healthcare partner hospitals, all patients undergo pre-operative MDT review, intraoperative frozen section margin analysis, and post-operative care within ERAS protocols, which collectively reduce major complication rates and improve recovery benchmarks compared to non-specialized centers.

Why GAF Healthcare

GAF Healthcare provides comprehensive, white-glove medical travel coordination for international patients pursuing pancreatic cancer treatment in India or the UAE, covering every logistical need from first inquiry to departure.

Common questions about Pancreatic Cancer Treatment

What is the cost of Pancreatic Cancer Treatment in India vs. the UAE?
The total cost of pancreatic cancer treatment varies by stage, treatment modality, and hospital tier. For a complete surgical episode (Whipple procedure or distal pancreatectomy including surgeon's fee, anesthesia, ICU care, private ward stay, pathology, and standard medications) at a JCI- or NABH-accredited hospital in India, the all-inclusive cost typically ranges from USD 6,000 to USD 18,000 — with robotic-assisted Whipple procedures and complex vascular reconstruction at the higher end. The same treatment at JCI- and DHA-licensed hospitals in Dubai or Abu Dhabi ranges from USD 15,000 to USD 40,000, reflecting premium infrastructure and higher operational costs in the UAE. For systemic chemotherapy-only programs (e.g., FOLFIRINOX or gemcitabine-nab-paclitaxel for locally advanced or metastatic disease), per-cycle costs in India range from USD 800–2,500 and in the UAE from USD 2,500–6,000 per cycle depending on the drug regimen. Targeted therapies (e.g., olaparib for BRCA-mutated cases) and NGS tumor profiling costs are additional. GAF Healthcare provides a personalized cost estimate within 48 hours of receiving the patient's medical records, with no hidden fees.
How long do I need to stay in the country before I am fit to fly home after Pancreatic Cancer Treatment?
The required in-country stay depends primarily on the treatment modality. For patients undergoing a Whipple procedure (pancreaticoduodenectomy) or distal pancreatectomy, the hospital stay is typically 7–14 days, followed by a mandatory post-discharge recovery period near the hospital for outpatient monitoring. Most pancreatic surgery patients are cleared as fit-to-fly at 4–6 weeks post-operatively, once the treating surgeon confirms: stable nutritional intake and tolerability of oral diet; no active drain, wound complication, or signs of fistula; adequate pain control on oral analgesics; and normal or acceptable post-operative imaging (CT at Week 3–4). Patients who undergo laparoscopic distal pancreatectomy (less invasive) may be cleared earlier, typically at 3–4 weeks. The total recommended in-country stay for surgical patients is therefore 5–8 weeks. For patients receiving chemotherapy initiation only (without surgery), the in-country stay is shorter — typically 2–3 weeks to complete the first cycle, assess tolerance, and receive oncology follow-up — before returning home to continue treatment locally. GAF Healthcare arranges a formal fit-to-fly assessment and provides the patient with a structured medical travel certificate, in-flight positioning guidelines, and LMWH (blood-clot prevention injection) instructions for long-haul flights, which are typically required for 5–7 days post-travel in post-surgical oncology patients.
What is the success rate of Pancreatic Cancer Treatment?
Success rates in pancreatic cancer treatment are stage-dependent and must be interpreted with clinical context. For surgically resected Stage I–II pancreatic ductal adenocarcinoma (PDAC) at high-volume centers (defined as >20 Whipple procedures annually), the 5-year overall survival rate is approximately 20–30%, with R0 (margin-negative) resection being the single most important prognostic factor. Median overall survival after resection followed by adjuvant modified FOLFIRINOX is 54 months (PRODIGE 24 trial), representing a major improvement over historical benchmarks. For borderline resectable disease treated with neoadjuvant FOLFIRINOX followed by surgery, 5-year survival rates of 25–30% are achievable in patients achieving a complete resection. For locally advanced (Stage III) unresectable PDAC, the median overall survival with current multimodal chemoradiation protocols is 12–20 months, with a subset of patients — particularly those with exceptional responses to FOLFIRINOX — becoming secondarily resectable and achieving long-term survival. For metastatic (Stage IV) PDAC, current systemic therapy achieves a median overall survival of 8–12 months with FOLFIRINOX or gemcitabine-nab-paclitaxel; however, molecularly selected subgroups fare significantly better — for example, BRCA1/2-mutated patients on maintenance olaparib achieve a median progression-free survival of 7.4 months versus 3.8 months on placebo (POLO trial), and MSI-H patients receiving pembrolizumab may achieve durable responses. GAF Healthcare partner centers in India and the UAE perform full molecular tumor profiling for every patient to identify all actionable targets, maximizing individualized treatment benefit.

How GAF Healthcare Assists in Choosing the Best Hospital for Pancreatic Cancer Treatment in Chennai, India

Discover the Top Hospitals for Pancreatic Cancer Treatment in Chennai, India

This page lists 8 accredited surgical oncology hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about pancreatic cancer treatment in Chennai, India

How many surgical oncology hospitals are listed in Chennai, India?
8 hospitals in our Chennai, India directory are currently listed for surgical oncology including Pancreatic Cancer Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there surgical oncology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
🤔

Still have questions?

Our coordinators are here to answer your questions about pancreatic cancer treatment in Chennai, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for pancreatic cancer treatment in Chennai, India.

Contact us to report an inaccuracy on this page.